DCTH Insider Trading
Insider Ownership Percentage: 17.94%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Delcath Systems Insider Trading History Chart
This chart shows the insider buying and selling history at Delcath Systems by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Delcath Systems Share Price & Price History
Current Price: $12.00
Price Change: ▼ Price Decrease of -0.98 (-7.55%)
As of 04/3/2025 05:00 PM ET
Delcath Systems Insider Trading History
Delcath Systems Institutional Trading History
Data available starting January 2016
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Read More on Delcath Systems
Today's Range
Now: $12.00
52 Week Range
Now: $12.00
Volume
434,586 shs
Average Volume
343,233 shs
Market Capitalization
$400.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.82
Who are the company insiders with the largest holdings of Delcath Systems?